ArticleIndian journal of surgical oncology2025
Non-Cancer-Related Causes' Impact on Lung Cancer Survival: SEER Analysis.
Article in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As lung cancer (LC) patients survive longer, non-cancer-related mortality risks are increasingly prominent, yet temporal trends and risk factors remain unclear. This study systematically evaluates standardized mortality ratios (SMRs) for non-cancer deaths and their temporal dynamics. We analyzed 371,177 lung cancer patients from tthe Surveillance, Epidemiology, and End Results (SEER) database (2000-2019), categorizing non-cancer-related deaths into six groups: infectious, diabetes, cardiovascular, respiratory, digestive, and others. SMRs were calculated, and Fine-Gray models assessed mortality risks. Non-cancer-related deaths rose significantly over time, increasing from 7.72% within 1 year to 53.97% beyond 5 years post-diagnosis (overall SMR = 2.24, 95% CI 2.22-2.26), surpassing cancer-specific mortality after 5 years. Cardiovascular (SMR = 4.85) and respiratory diseases (SMR = 3.56) were predominant, with peak non-cancer mortality at 1-5 years (SMR = 2.33). Multivariate analysis identified advanced age, male sex, advanced-stage cancer, and lack of active treatment as key risk factors. This mortality shift, driven by aging and treatment-related complications, underscores the need for multidisciplinary survivorship programs. Prioritizing cardiovascular monitoring, lifestyle interventions (e.g., smoking cessation), and structured follow-up for untreated patients may reduce preventable deaths. These strategies address critical gaps in long-term management, improving survival and quality of life for lung cancer survivors. Supplementary Information: The online version contains supplementary material available at 10.1007/s13193-025-02458-7.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.